Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy for many patients with hematologic malignancies and marrow failure. A critical hurdle in accomplishment of successful HSCT has been graft-versus-host disease (GVHD).The ultimate objective of the research projects in this renewal application is to further improve our understanding of the pathophysiology of aGVHD and cGVHD and to develop novel strategies for both prevention and therapy of cGVHD by targeting distinct cellular populations in these two syndromes while maintaining GVL. Key to achieve this objective and thus to lead to the success of this program project is dynamic biostatistical collaboration with individuals in each of the 3 projects and the 3 other Cores. The purpose of the Biostatistics Core C is to provide the following services that will be utilized by the research projects included in this Program Project. 1. To provide biostatistical collaboration for translational clinical research studies. 2. To provide biostatistical collaboration for translational animal research studies. 3. To provide biostatistical and/or bioinformatics collaboration for translational laboratory research studies. 4. To provide research infrastructure for translational research. 5. To provide computing resources for data processing, and statistical analysis, standardized reporting, and quality control.

Public Health Relevance

Preventing or treating cGVHD, thus reducing related morbidity and mortality, is important because 1) improvements in HSCT technology allow the use of older donors and older patients to receive transplant, thus more patients undergo HSCT, and 2) improvements in supportive care result in better survival in later time periods when cGVHD occurs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA142106-10
Application #
8468140
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
Project End
2015-03-31
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
10
Fiscal Year
2013
Total Cost
$203,783
Indirect Cost
$69,895
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Bachireddy, Pavan; Hainz, Ursula; Rooney, Michael et al. (2014) Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. Blood 123:1412-21
Dubovsky, Jason A; Flynn, Ryan; Du, Jing et al. (2014) Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest 124:4867-76
Koreth, John; Kim, Haesook T; Nikiforow, Sarah et al. (2014) Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival. Biol Blood Marrow Transplant 20:1516-21
Herrera, Alex F; Kim, Haesook T; Bindra, Bhavjot et al. (2014) A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease. Biol Blood Marrow Transplant 20:1737-43
Gazourian, Lee; Rogers, Angela J; Ibanga, Ruby et al. (2014) Factors associated with bronchiolitis obliterans syndrome and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. Am J Hematol 89:404-9
Socié, Gérard; Ritz, Jerome (2014) Current issues in chronic graft-versus-host disease. Blood 124:374-84
Armand, Philippe; Kim, Haesook T; Virtanen, Johanna M et al. (2014) Iron overload in allogeneic hematopoietic cell transplantation outcome: a meta-analysis. Biol Blood Marrow Transplant 20:1248-51
Alexander, Kylie A; Flynn, Ryan; Lineburg, Katie E et al. (2014) CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease. J Clin Invest 124:4266-80
Kim, Haesook T; Frederick, David; Armand, Philippe et al. (2014) White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome. Am J Hematol 89:591-7
Pai, Chien-Chun Steven; Chen, Mingyi; Mirsoian, Annie et al. (2014) Treatment of chronic graft-versus-host disease with bortezomib. Blood 124:1677-88

Showing the most recent 10 out of 68 publications